Primary resistance to ALK inhibitors in -rearranged pleural metastatic lung adenocarcinoma: a case report.
Fiche publication
Date publication
novembre 2023
Journal
Translational lung cancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PENCREACH Erwan, Dr SCHOTT Roland, Dr BENDER Laura
Tous les auteurs :
Siblini L, Schott R, Trensz P, Pencreach E, Bender L
Lien Pubmed
Résumé
Anaplastic lymphoma kinase () rearrangement confers sensitivity to second- and third-generation ALK inhibitors, which have become the standard of care for ALK-positive non-small cell lung carcinoma (NSCLC). However, primary resistance to these inhibitors remains a rare and poorly understood phenomenon, especially in cases involving kinesin light chain 1 ()/-rearranged metastatic NSCLC.
Mots clés
Kinesin light chain 1/anaplastic lymphoma kinase rearrangement (KLC1/ALK rearrangement), case report, non-small-lung carcinoma, primary resistance
Référence
Transl Lung Cancer Res. 2023 11 30;12(11):2342-2346